Monocyte migrations

LMU researchers led by Christian Weber have, for the first time, elucidated how cells that promote the development of atherosclerosis find their way to the blood vessel wall, where they stimulate the formation of obstructive deposits.

Atherosclerosis is one of the commonest causes of death in modern societies. The condition is characterized by the build-up of called atherosclerotic plaques on the inner surfaces of arteries, which restrict, and may eventually cut off, blood flow. The deposits can also be dislodged from their site of origin and may then block major vessels in the heart or the brain, leading to life-threatening or stroke.

Monocytes, an important class of , are known to contribute significantly to the development of atherosclerosis. They are actively recruited to atherosclerotic lesions, and promote plaque development by sustaining a chronic inflammatory reaction.

Inhibition of monocyte recruitment therefore offers a way of interrupting the build-up of plaques. However, one first needs to know how the monocytes are actually localized to the . Professor Christian Weber and Dr. Maik Drechsler of the Institute for and Epidemiology of Cardiovascular Disease at LMU, in collaboration with Oliver Söhnlein of LMU and a team at the Academic Medical Center in Amsterdam, have now shown that the receptor molecules CCR1 and CCR5 are crucially involved in the process by which monocytes are recruited to the vessel wall. This process is made up of a sequence of distinct steps, including adhesion of the that form the arterial wall, and their subsequent transmigration into the bloodstream by infiltration between neighboring endothelial cells, following activation of the receptors by binding of their respective .

The new findings correct a commonly held view of the precise function of the CCR2 receptor in the recruitment of monocytes. "In contrast to what has been assumed so far, this receptor does not mediate the infiltration of monocytes into the vessel wall; instead, like another chemokine receptor, CXCR2, it controls their mobilization from the bone marrow into the bloodstream," says Oliver Söhnlein.

The receptor molecules CCR1 and CCR5 therefore present promising targets for the development of novel approaches to the treatment of atherosclerosis, using agents that inhibit their interaction with their respective binding partners, either directly or indirectly.

More information: EMBO Molecular Medicine doi: 10.1002/emmm.201201717

add to favorites email to friend print save as pdf

Related Stories

Extending the effective lifetime of stents

Oct 06, 2011

Implanted stents can reopen obstructed arteries, but regrowth of cells into the vessel wall can entail restenosis. Research at LMU now shows that an antimicrobial peptide inhibits restenosis and promotes vascular healing. ...

Fast track to vascular disease

Jun 03, 2011

In Western societies, atherosclerosis of the arteries is one of the leading causes of death. Chronic, localized inflammation of the blood vessel wall facilitates the growth of fibrous plaques, which leads to narrowing or ...

Inflammation worsens danger due to atherosclerosis

Jan 22, 2009

Current research suggests that inflammation increases the risk of plaque rupture in atherosclerosis. The related report by Ovchinnikova et al, "T cell activation leads to reduced collagen maturation in atherosclerotic plaques ...

Recommended for you

Organovo has 3D-printed liver tissue for drug testing

Nov 20, 2014

(Medical Xpress)—The commercial release of 3D printed liver tissue was announced earlier this week. Organovo is the company behind the release. The product is intended for use for preclinical drug discovery ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.